BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 21037108)

  • 1. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
    Namdar M; Perez G; Ngo L; Marks PA
    Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
    Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
    Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a histone deacetylase 6 inhibitor and its biological effects.
    Lee JH; Mahendran A; Yao Y; Ngo L; Venta-Perez G; Choy ML; Kim N; Ham WS; Breslow R; Marks PA
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15704-9. PubMed ID: 24023063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase-6 inhibitor tubacin directly inhibits de novo sphingolipid biosynthesis as an off-target effect.
    Siow D; Wattenberg B
    Biochem Biophys Res Commun; 2014 Jul; 449(3):268-71. PubMed ID: 24835950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.
    Aldana-Masangkay GI; Rodriguez-Gonzalez A; Lin T; Ikeda AK; Hsieh YT; Kim YM; Lomenick B; Okemoto K; Landaw EM; Wang D; Mazitschek R; Bradner JE; Sakamoto KM
    Leuk Lymphoma; 2011 Aug; 52(8):1544-55. PubMed ID: 21699378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
    Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
    Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HDAC6 Inhibitor Tubacin Induces Release of CD133
    Chao OS; Chang TC; Di Bella MA; Alessandro R; Anzanello F; Rappa G; Goodman OB; Lorico A
    J Cell Biochem; 2017 Dec; 118(12):4414-4424. PubMed ID: 28452069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
    Lu CY; Chang YC; Hua CH; Chuang C; Huang SH; Kung SH; Hour MJ; Lin CW
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
    Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
    PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
    Komatsu S; Moriya S; Che XF; Yokoyama T; Kohno N; Miyazawa K
    Biochem Biophys Res Commun; 2013 Jul; 437(1):41-7. PubMed ID: 23792097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
    Haggarty SJ; Koeller KM; Wong JC; Grozinger CM; Schreiber SL
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4389-94. PubMed ID: 12677000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
    Heinicke U; Fulda S
    Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
    Pai JT; Hsu CY; Hua KT; Yu SY; Huang CY; Chen CN; Liao CH; Weng MS
    Molecules; 2015 May; 20(5):8000-19. PubMed ID: 25946558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.
    Conti C; Leo E; Eichler GS; Sordet O; Martin MM; Fan A; Aladjem MI; Pommier Y
    Cancer Res; 2010 Jun; 70(11):4470-80. PubMed ID: 20460513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
    Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules.
    Husain M; Cheung CY
    J Virol; 2014 Oct; 88(19):11229-39. PubMed ID: 25031336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.
    Alothaim T; Charbonneau M; Tang X
    Sci Rep; 2021 May; 11(1):10956. PubMed ID: 34040090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
    Kolbinger FR; Koeneke E; Ridinger J; Heimburg T; Müller M; Bayer T; Sippl W; Jung M; Gunkel N; Miller AK; Westermann F; Witt O; Oehme I
    Arch Toxicol; 2018 Aug; 92(8):2649-2664. PubMed ID: 29947893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.